RARE

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

Recent trades

Signal

Neutral signalScored 2026-10-25 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.

RARE presents a moderate event-driven signal anchored by congressional purchases and two significant PRV sales ($203M and $210M) providing non-dilutive cash injections, partially offsetting deeply stressed fundamentals.

The first sentence of the analysis written for RARE on 2026-10-25 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Recent news

• 2026-10-20 Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report) CFO Howard Horn sold 7,066 shares of the company''s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the completion of the transaction, the chief financial officer owned 89,229 shares of
• 2026-10-15 RARE''s Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
• 2026-10-14 Can RARE''s Approved Product Portfolio Drive Its Next Growth Phase? Ultragenyx''s established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
• 2026-10-14 Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million Agreement marks the Company''s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company''s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction
• 2026-10-14 Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Taiwan Semiconductor Manufacturing stock on September 22nd. The trade occurred in the Representative''s "150 MAIN STREET TRUST > BANK OF
• 2026-10-12 Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE) Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. Profitability This table compares Atara Biotherapeutics and
• 2026-10-08 Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
• 2026-10-07 Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded to Ultragenyx after the US Food and Drug Administration approved GENGLYCOS, also known as DTX401, for glycogen storage disease (GSD) type Ia.
• 2026-10-07 Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).
• 2026-10-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Market snapshot

Financial ratios

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

Key metrics

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Change over 5 years

Employee count

Peer market caps